Black Diamond Therapeutics reports Q1 EPS (35c), consensus (43c)

Cash, cash equivalents, and investments of $115.2M as of March 31, 2024, is expected to be sufficient to fund operations into Q3 of 2025. “We reached an important inflection in BDTX-1535 development this past quarter, as we initiated dosing of patients with non-classical EGFR mutant NSCLC in the first-line setting, and are on track to release initial results from the ongoing Phase 2 second/third-line cohorts in Q3 of this year “, said CEO Mark Velleca. “Our recent AACR presentation on the evolving EGFR mutation landscape highlights the major unmet need in EGFR mutant NSCLC, and the differentiated BDTX-1535 profile as the potential first- and best-in-class fourth-generation oral TKI in clinical development addressing the full spectrum of classical, non-classical, and C797S resistance mutations in NSCLC.”